AI Patient Education Module for Breast Cancer
This study is testing a new artificial intelligence (AI) tool called OpenEvidence CareConnect. This tool is designed to help educate patients with breast cancer. Researchers want to see how safe and accurate it is, and how well it helps patients understand their condition and communicate with their care team. You might be able to join if you are 18 or older and have Stage IV breast cancer facing a treatment change, or Stage I-III breast cancer diagnosed within the last 6 months. You also need basic computer skills and internet access. The study will look at how helpful patients and providers find the tool, and how it affects communication. The study plans to enroll 35 participants.
- Study design
- This study will first have 5 participants in a lead-in phase, then 30 participants will be randomly assigned to either use the AI tool or be on a waitlist. It is an interventional study.
- What's involved
- You will complete surveys about your experience using the OpenEvidence CareConnect tool. The study measures will be taken for up to 90 months or up to 180 days, depending on the specific measurement.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 90 months for some safety assessments, and up to 180 days for other assessments of the AI tool.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Generative AI Patient Education Module for Breast Oncology
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michelle Melisko, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Mean score of Safety and Risk Assessment (Lead-in and Provider)Up to 90 months
Safety and Risk Assessment evaluates safety concerns based on provider responses using a 5-point Likert scale.
- Mean score of Provider Assessment of AI patient Education Tool Survey (Provider)Up to 180 days
AI patient Education Tool Survey evaluates clinical accuracy and appropriateness of the OpenEvidence CareConnect tool based on provider responses using a 5-point Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree).
- Mean score of Assessment of Answer Accuracy and Content Appropriateness (Provider)Uup to 180 days
Provider will evaluate participant questions, answer accuracy and content provided within the OpenEvidence using 3-point scales.